CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to ...

A federal judge ordered CVS Health's pharmacy benefit manager unit to pay $289.9 million in damages and penalties after it ...

Shares in biopharmaceutical group Gilead Sciences ($GILD) dropped 1% today after pharmacy firm CVS Health ($CVS) gave the ...

CVS Health, which operates the largest U.S. pharmacy benefit manager, will not add Gilead Sciences’ new HIV prevention drug ...

Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying. Executives at Gilead Sciences, the biotech behind a ...

The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV ...

CVS Health (NYSE:CVS), one of the leading health insurers in the U.S. and owner of the Pharmacy Benefit Manager Caremark, ...

CVS Health is not entitled to coverage from insurers, including AIG and Chubb , against thousands of lawsuits over its role ...

After Reuters reported that CVS Health (CVS) will not cover Gilead’s (GILD) Yeztugo for HIV PrEP therapy in their commercial and ACA plans, ...

CVS Health is not entitled to coverage from insurers, including AIG and Chubb, against thousands of lawsuits over its role in ...

Investing.com -- Gilead Sciences (NASDAQ: GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE: CVS) will not add the company’s new HIV prevention drug, Yeztugo, to ...

CVS Health (CVS) won’t add Gilead’s (GILD) new HIV prevention drug to its commercial plans for now, despite the medication’s proven effectiveness, a spokesperson tells Reuters, Deena Beasley reports.